Wendy's Board Blocks Peltz's Buyout with Poison Pill

Wendy’s Board Rejects Trian Take-Private Bid

Wendy’s (WEN) independent committees’ unanimous rejection of Trian’s $1.4 billion take-private proposal signals the board’s confidence in CEO Bob Wright’s ongoing turnaround strategy and its view that Wall Street is dramatically undervaluing the company. Declining the offer tells Wall Street that the board believes in Wright’s plan to rebuild Wendy’s value menu, use digital means to drive loyalty, and revamp the franchisee unit economics.

Taking the “Poison Pill”

Trian Partners, an activist hedge fund run by Nelson Peltz, is well known on Wall Street for buying large stakes in underperforming public companies to gain leverage to push operational and strategic change. In addition to declining Trian’s offer, the independent Wendy’s board is doubling down on its turnaround bet by using a strategy called the “Poison Pill.” The Poison Pill is a defensive strategy boards use to prevent Trian or any other activist investor consortium from accumulating enough shares to gain voting control. In other words, Trian will be unable to acquire Wendy’s through back-door means.

What’s Next for Wendy’s & Trian?

For now, the offer is good news for Wendy’s shareholders because it will put an artificial floor beneath shares at ~$7.35 (Trian’s offer price). Nevertheless, a lot of uncertainty remains. Trian currently holds a 16% stake in Wendy’s. Now that the board has adopted the Poison Pill, Peltz and Trian will need to decide whether to sweeten the offer, stage a proxy fight, or get on board with Bob Wright’s turnaround attempts.

The Ball is in Wendy’s Court

The ball is in Wendy’s court. If Wright’s turnaround shows progress over the next few quarters, the company will garner a higher valuation. However, if sales remain stagnant, Peltz and Trian will gain more leverage and potentially more board seats. For now, Wendy’s has outperformed lowered Wall Street expectations. The Zacks Rank #2 (Buy) stock has beaten Zacks Consensus Analyst Estimates by an average of 16.70% over the past four quarters.

Bottom Line

By turning down Trian’s bid and enacting a defensive poison pill, Wendy’s leadership is sending a strong message of confidence in its standalone turnaround plan. While the board's decisive move sets a temporary price floor for investors, pressure remains on CEO Bob Wright to deliver sustained top- and bottom-line growth in the coming quarters. Should sales stall, Nelson Peltz and Trian will inevitably gain the leverage needed to push for aggressive strategic changes.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research